Beryl Drugs Ltd (524606) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 524606 | NSE: | Pharmaceuticals & Drugs | Small Cap

Beryl Drugs Share Price

21.74 -0.51 -2.29%
as on 05-Dec'25 11:28

Beryl Drugs Ltd (524606) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 524606 | NSE: | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Beryl Drugs

Based on:

M-Cap below 100cr DeciZen not available

Beryl Drugs stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
48.22
Market Cap:
11.3 Cr.
52-wk low:
17.4
52-wk high:
43.7

Is Beryl Drugs Ltd an attractive stock to invest in?

1. Is Beryl Drugs Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Beryl Drugs Ltd is a below average quality company.

2. Is Beryl Drugs Ltd undervalued or overvalued?

The key valuation ratios of Beryl Drugs Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Beryl Drugs Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Beryl Drugs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Beryl Drugs:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Beryl Drugs Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 5.6%4.5%16.9%10%4.1%6.3%-3.8%11.5%11.1%10.2%-
Value Creation
Index
-0.6-0.70.2-0.3-0.7-0.6-1.3-0.2-0.2-0.3-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 13.11115.11312.814.114.626.926.721.219
Sales YoY Gr.--16.2%37.8%-14.4%-1.1%9.9%3.6%84%-0.5%-20.9%-
Adj EPS 0.20.21.31.20.1-0.2-1.31.51.51.10.5
YoY Gr.-16.7%528.6%-10.6%-92.4%-266.7%NANA-0.7%-24%-
BVPS (₹) 13.113.413.114.81515.614.315.917.618.718.6
Adj Net
Profit
0.10.10.70.60.1-0.1-0.70.80.80.60
Cash Flow from Ops. -0.10.3-0.13.40.20.3-0.52.40.82.6-
Debt/CF from Ops. -13.56.3-14.8128.315.1-11.31.96.21.6-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 5.5%10.5%13.2%-20.9%
Adj EPS 22.8%66.2%NA-24%
BVPS4%4.5%9.3%6.6%
Share Price -4.9% 25.4% 19.9% -35%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
1.41.6108.40.6-1-8.61096.32.5
Op. Profit
Mgn %
3.84.56.987.110.337.48.24.712.4
Net Profit
Mgn %
0.714.44.60.4-0.5-4.52.92.92.71.2
Debt to
Equity
0.30.30.20.40.70.70.70.60.60.40.2
Working Cap
Days
17021518519518623226614615117687
Cash Conv.
Cycle
104149114957293114587611237

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 13.15%

Debt to equity has declined versus last 3 years average to 0.43

Return on Equity has declined versus last 3 years average to 2.50%

Net Profit has been subdued in last 3 years 0.00%

Sales growth is not so good in last 4 quarters at -7.30%

Latest Financials - Beryl Drugs Ltd.

Standalone Consolidated
TTM EPS (₹) 0.5 -
TTM Sales (₹ Cr.) 19.2 -
BVPS (₹.) 18.6 -
Reserves (₹ Cr.) 4 -
P/BV 1.19 -
PE 48.22 -
From the Market
52 Week Low / High (₹) 17.35 / 43.70
All Time Low / High (₹) 0.60 / 53.00
Market Cap (₹ Cr.) 11.3
Equity (₹ Cr.) 5.1
Face Value (₹) 10
Industry PE 40.7

Management X-Ray of Beryl Drugs:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Beryl Drugs - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Beryl Drugs

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales13.1110.9915.1412.9612.8214.0914.6026.8726.7321.15
Operating Expenses 12.6110.5014.1011.9411.9112.6414.1724.8824.5320.15
Manufacturing Costs8.917.079.447.497.828.779.8817.0616.5714
Material Costs1.511.151.691.440.870.730.601.571.310.78
Employee Cost 1.130.900.770.850.851.031.131.491.722
Other Costs 1.061.382.202.162.372.122.564.774.933.36
Operating Profit 0.500.491.041.020.911.450.431.992.201
Operating Profit Margin (%) 3.8%4.5%6.9%7.9%7.1%10.3%3.0%7.4%8.2%4.7%
Other Income 0.370.260.690.240.230.190.160.280.481.65
Interest 0.210.210.130.150.320.470.460.470.470.54
Depreciation 0.410.380.330.320.661.271.090.811.201.25
Exceptional Items 000000.450000
Profit Before Tax 0.250.171.270.800.160.35-0.950.981.010.87
Tax 0.080.050.280.210.110.11-0.290.220.240.29
Profit After Tax 0.170.120.990.590.050.24-0.660.770.770.58
PAT Margin (%) 1.3%1.1%6.6%4.6%0.4%1.7%-4.5%2.9%2.9%2.7%
Adjusted EPS (₹)0.30.22.01.20.10.5-1.31.51.51.1
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 6.666.796.677.537.637.937.298.078.929.50
Share Capital 5.095.095.095.095.095.095.095.095.095.09
Reserves 1.571.701.572.432.532.842.202.973.834.41
Minority Interest0000000000
Debt1.681.691.463.054.714.345.294.545.094.07
Long Term Debt00.090.071.302.311.991.682.712.401.74
Short Term Debt1.671.601.391.762.392.353.621.842.692.34
Trade Payables0.741.161.451.791.802.223.063.252.021.12
Others Liabilities 0.821.431.222.122.784.1621.621.671.34
Total Liabilities 9.9111.0710.8014.4916.9118.6517.6517.4817.7116.03

Fixed Assets

Gross Block8.969.152.672.549.8410.099.6910.4411.6512.93
Accumulated Depreciation6.526.890.620.871.502.763.834.635.686.92
Net Fixed Assets 2.442.262.041.678.347.335.865.815.966.01
CWIP 000.086.24000000
Investments 0.680.680.390.770.820.120.160.1500
Inventories1.542.691.350.761.162.272.981.051.261.90
Trade Receivables3.533.604.833.443.454.544.456.907.585.46
Cash Equivalents 0.630.770.140.100.400.450.670.570.120.81
Others Assets 1.071.081.971.522.743.943.532.992.771.86
Total Assets 9.9111.0710.8014.4916.9118.6517.6517.4817.7116.03

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity -0.130.27-0.103.350.180.34-0.472.390.822.64
PBT 0.270.171.270.800.160.35-0.950.981.010.87
Adjustment 0.660.40-0.390.280.831.141.371.121.531.64
Changes in Working Capital -0.54-0.13-0.872.53-0.66-1.13-0.850.35-1.520.31
Tax Paid -0.16-0.12-0.11-0.26-0.15-0.02-0.03-0.06-0.20-0.18
Cash Flow From Investing Activity 0.170.05-0.03-5.01-1.550.260.52-1.18-1.08-0.40
Capex -0.20-0.200.17-0.06-1.88-0.240.40-0.75-1.33-1.28
Net Investments 000.28000.97000.220
Others 0.370.25-0.48-4.950.32-0.480.13-0.430.030.88
Cash Flow From Financing Activity -0.23-0.19-0.361.621.67-0.54-0.24-1.200.10-1.55
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 00.09-0.021.391.35-0.07-0.311.03-0.25-0.66
Interest Paid -0.21-0.20-0.13-0.15-0.32-0.47-0.41-0.44-0.46-0.53
Dividend Paid 0000000000
Others -0.02-0.08-0.210.370.64-00.48-1.800.81-0.36
Net Cash Flow -0.190.13-0.49-0.040.300.06-0.180.01-0.160.69

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)2.541.7414.88.350.633.09-8.68109.076.3
ROCE (%)5.554.4816.889.964.056.28-3.8211.5111.1410.15
Asset Turnover Ratio1.321.091.41.020.820.790.81.531.521.25
PAT to CFO Conversion(x)-0.762.25-0.15.683.61.42N/A3.11.064.55
Working Capital Days
Receivable Days97114100116981041127799113
Inventory Days41674830274466271627
Payable Days2863022824107551,0061,617735734730

Beryl Drugs Ltd Stock News

Beryl Drugs Ltd FAQs

The current trading price of Beryl Drugs on 05-Dec-2025 11:28 is ₹21.74.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Beryl Drugs stood at ₹11.28.
The latest P/E ratio of Beryl Drugs as of 04-Dec-2025 is 48.22.
The latest P/B ratio of Beryl Drugs as of 04-Dec-2025 is 1.19.
The 52-week high of Beryl Drugs is ₹43.70 and the 52-week low is ₹17.35.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Beryl Drugs is ₹19.20 ( Cr.) .

About Beryl Drugs Ltd

Beryl Drugs incorporated in 1993 is into manufacturing and marketing of branded, generic pharmaceutical formulations. The company is one of leading manufacturer of I.V.fluids and small volume injectables.

Beryl has emerged into a global network of pharmaceutical manufacturing, research and development, contract manufacturing services and veterinary products. 

The manufacturing facilities of the company are in compliance with WHO GMP specifications.

Company owns brands like BERI-CEF injection, F-Neuron, Amplicillin INJ, P-Mol, Biprox, B-Flox and many more.

The shares of Beryl Drugs are listed on M.P. Stock Exchange, Bombay Stock Exchange and Ahmedabad Stock Exchange.

Products manufactured by the company:

  • Small volume injectables in liquid form
  • Small volume injectables in dry powder form
  • Variety of eye and ear drops
  • I.V.Fluids in polypack and glass bottles
  • Variety of vetrinary medicines

Award/recognition

The company has received ISO 9001:2000 certification for its quality management.

You have 1 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×